Total Funding
29
53
Total FundingPost-IPO Equity raised
Growth Score
-1 pts
Heat Score
-6 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
293085
Nutraceutical biotechnology company focused on alternative plant-based cannabinoids and psilocybin medical research
Michael Sachar: CEO
About the Company
M2bio Sciences Inc. formerly Wuhan General Group, Inc. is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids and psilocybin medical research that develops and commercializes a range of CBD and mushrooms based products under Dr. AnnaRx™, Medspresso™ and Handcrafted Delights™ brands. In addition, our research and
clinical trials with psilocybin are aimed for new therapies that will help patients who suffer from alcohol addiction, mental illness and heart diseases.
